4D Molecular Therapeutics (FDMT) EBIT Margin: 2020-2025
Historic EBIT Margin for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Sep 2025 value amounting to -67,983.33%.
- 4D Molecular Therapeutics' EBIT Margin rose 163641667.00% to -67,983.33% in Q3 2025 from the same period last year, while for Sep 2025 it was -191,982.50%, marking a year-over-year increase of 79846456.00%. This contributed to the annual value of -507,678.38% for FY2024, which is 50713373.00% down from last year.
- According to the latest figures from Q3 2025, 4D Molecular Therapeutics' EBIT Margin is -67,983.33%, which was up 82.85% from -396,373.33% recorded in Q2 2025.
- Over the past 5 years, 4D Molecular Therapeutics' EBIT Margin peaked at 192,905.26% during Q4 2023, and registered a low of -5,611,700.00% during Q4 2024.
- For the 3-year period, 4D Molecular Therapeutics' EBIT Margin averaged around -816,317.86%, with its median value being -136,200.00% (2024).
- In the last 5 years, 4D Molecular Therapeutics' EBIT Margin crashed by 580,460,526bps in 2024 and then soared by 163,641,667bps in 2025.
- Quarterly analysis of 5 years shows 4D Molecular Therapeutics' EBIT Margin stood at -26,917.39% in 2021, then soared by 2,461,426bps to -2,303.13% in 2022, then soared by 19,520,839bps to 192,905.26% in 2023, then slumped by 580,460,526bps to -5,611,700.00% in 2024, then soared by 163,641,667bps to -67,983.33% in 2025.
- Its EBIT Margin was -67,983.33% in Q3 2025, compared to -396,373.33% in Q2 2025 and -383,007.14% in Q1 2025.